Tumoral PD-L1 expression defines a subgroup of poor-prognosis vulvar carcinomas with non-viral etiology by Hecking, Thomas et al.
Tumoral PD-L1 expression defines a
subgroup of poor-prognosis vulvar
carcinomas with non-viral etiology
The Harvard community has made this
article openly available.  Please share  how
this access benefits you. Your story matters
Citation Hecking, T., T. Thiesler, C. Schiller, J. Lunkenheimer, T. H. Ayub,
A. Rohr, M. Condic, et al. 2017. “Tumoral PD-L1 expression
defines a subgroup of poor-prognosis vulvar carcinomas with
non-viral etiology.” Oncotarget 8 (54): 92890-92903. doi:10.18632/
oncotarget.21641. http://dx.doi.org/10.18632/oncotarget.21641.
Published Version doi:10.18632/oncotarget.21641
Citable link http://nrs.harvard.edu/urn-3:HUL.InstRepos:34493168
Terms of Use This article was downloaded from Harvard University’s DASH
repository, and is made available under the terms and conditions
applicable to Other Posted Material, as set forth at http://
nrs.harvard.edu/urn-3:HUL.InstRepos:dash.current.terms-of-
use#LAA
Oncotarget92890www.impactjournals.com/oncotarget
Tumoral PD-L1 expression defines a subgroup of poor-prognosis 
vulvar carcinomas with non-viral etiology
Thomas Hecking1,*, Thore Thiesler2,*, Cynthia Schiller2, Jean-Marc Lunkenheimer2,4, 
Tiyasha H. Ayub1, Andrea Rohr1,5, Mateja Condic1, Mignon-Denise Keyver-Paik1, 
Rolf Fimmers3, Jutta Kirfel2, Walther Kuhn1, Glen Kristiansen2,* and Kirsten 
Kübler1,6,7,8,*
1Department of Obstetrics and Gynecology, Center for Integrated Oncology, University of Bonn, Bonn, Germany
2Institute of Pathology, Center for Integrated Oncology, University of Bonn, Bonn, Germany
3Institute of Medical Biometry, Informatics and Epidemiology, Center for Integrated Oncology, University of Bonn, Bonn, 
Germany
4Hospital of Augustinian Nuns, Cologne, Germany
5Ärzte am Bärenplatz, Hornberg, Germany
6Broad Institute of MIT and Harvard, Cambridge, MA, USA
7Center for Cancer Research, Massachusetts General Hospital, Boston, MA, USA
8Harvard Medical School, Boston, MA, USA
*These authors have contributed equally to this work
Correspondence to: Kirsten Kübler, email: Kirsten.Kuebler@ukb.uni-bonn.de
Keywords: vulvar cancer, PD-L1, immune checkpoint, prognostic factor, HPV
Received: June 27, 2017    Accepted: August 25, 2017    Published: October 06, 2017
Copyright: Hecking et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License 
3.0 (CC BY 3.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and 
source are credited.
ABSTRACT
Vulvar cancer is rare but incidence rates are increasing due to an aging 
population and higher frequencies of young women being affected. In locally 
advanced, metastatic or recurrent disease prognosis is poor and new treatment 
modalities are needed. Immune checkpoint blockade of the PD-1/PD-L1 pathway 
is one of the most important advancements in cancer therapy in the last years. 
The clinical relevance of PD-L1 expression in vulvar cancer, however, has not been 
studied so far. We determined PD-L1 expression, numbers of CD3+ T cells, CD20+ B 
cells, CD68+ monocytes/macrophages, Foxp3+ regulatory T cells and CD163+ tumor-
associated macrophages by immunohistochemistry in 103 patients. Correlation 
analysis with clinicopathological parameters was undertaken; the cause-specific 
outcome was modeled with competing risk analysis; multivariate Cox regression 
was used to determine independent predictors of survival. Membranous PD-L1 
was expressed in a minority of tumors, defined by HPV-negativity. Its presence 
geographically correlated with immunocyte-rich regions of cancer islets and was 
an independent prognostic factor for poor outcome. Our data support the notion 
that vulvar cancer is an immunomodulatory tumor that harnesses the PD-1/PD-L1 
pathway to induce tolerance. Accordingly, immunotherapeutic approaches might 
have the potential to improve outcome in patients with vulvar cancer and could 
complement conventional cancer treatment.
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INTRODUCTION
Vulvar cancer - with squamous cell carcinoma 
(VSCC) being the predominant histologic subtype - is 
only the fourth most common tumor of the female genital 
tract, accounting for 5% of all gynecologic malignancies 
in developed countries [1]. However, overall incidence 
rates are increasing, mainly attributable to a strong 
rise in younger women [2–4]. Etiology divides VSCC 
into two subtypes: (i) human papillomavirus (HPV)-
associated tumors, typically diagnosed in younger 
women; and (ii) tumors arising in the background of lichen 
sclerosus et atrophicus, mostly seen in advanced age [5]. 
Approximately 65% of VSCCs are HPV-positive and the 
oncogenic high-risk types HPV-16/-18/-31/-33 are most 
frequently detected [6]. However, the burden of VSCC 
still lies with older women, in whom survival rates are low 
due to more aggressive tumors, diagnosis at later stages 
and frequent under-treatment [7, 8]. Surgery - consisting 
of local tumor excision with sentinel or inguinofemoral 
lymph node dissection - is considered the cornerstone of 
therapy. It leads to an excellent 5-year survival rate of 86% 
in localized VSCC [9]. Patients with locally advanced, 
metastatic or recurrent disease are additionally treated 
with radio- and chemotherapy. But the outcome is still 
poor and new therapeutic options are needed to reduce 
mortality in these women [10].
The recent success of checkpoint blockade caused 
a paradigm shift in cancer treatment. It focuses on 
disinhibiting tumor-specific immune responses. One 
of the most important immune-inhibitory checkpoint 
pathways consists of (i) the programmed death 1 (PD-
1) receptor, expressed on activated T cells; and (ii) the 
programmed death ligand 1 (PD-L1), expressed on 
tumor cells [11]. Their interaction negatively regulates 
T cell proliferation and function. This process allows 
the tumor to evade immune detection. PD-L1 levels 
were found to be present on various solid cancer types, 
typically conferring a poor prognosis [12–15]. Blockade 
of the PD-1/PD-L1 signaling pathway was demonstrated 
to enhance T cell function and has been successfully 
used in the treatment of multiple tumor types [16]. To 
bring attention to the opportunity checkpoint blockade 
might offer to VSCC, we here evaluate the clinical 
impact of PD-L1 expression. Our approach is motivated 
by two observations. First, VSCC is able to provoke a 
tumor-specific immune response. Both pro-inflammatory 
subsets and immunosuppressive mechanisms have been 
described [17–19]. Second, the clinical response to 
immune checkpoint blockade is correlated with tumor 
PD-L1 expression across multiple malignancies [20]. To 
form the basis for future use of checkpoint inhibitors in 
VSCC we here aim to analyze (i) the expression status 
of PD-L1; (ii) its relation to tumor biology; and (iii) its 
prognostic value.
RESULTS
VSCC is characterized by an immune-active 
tumor microenvironment
We first evaluated whether VSCC is a malignancy 
able to elicit an inflammatory response using samples 
that cover the wide range of the disease (Table 1). 
Several cellular components of the immune system 
were evaluated in cancer cell nests and the stroma 
separately. We found CD3+ T cells, CD20+ B cells 
and CD68+ monocytes/macrophages to be present in 
both compartments (Table 2). Immunosuppressive 
cell populations analyzed included Foxp3+ regulatory 
T cells (Treg cells) and CD163
+ tumor-associated 
macrophages (TAMs), shown to play a crucial role in 
various cancer types [21, 22]. These anti-inflammatory 
cell types also existed in both the tumor and the stroma 
(Supplementary Table 1). For all immune cell types 
analyzed frequencies in the stroma predominated over 
numbers in tumor islets.
VSCC express PD-L1 at variable degrees of 
intensity
In the next step, we aimed to determine whether 
additional immune escape mechanisms of the tumor are 
present. Membranous expression of PD-L1 was identified 
in 23.3% (24/103) VSCC samples. The intensity of 
continuously stained cell membranes ranged from low (3 
cases) to moderate (4 cases) to high (13 cases); four cases 
lacked confluence of staining (Figure 1A). The amount of 
stained cells varied between 5 and 60%; no positive case 
exhibited less than 5% of PD-L1 stained cells. To more 
closely reflect the biological reality we applied a stringent 
threshold. Using this cut-off, 9.7% (10/103) VSCCs were 
classified as PD-L1 positive (Table 2).
Immune activation is associated with PD-L1 
expression in VSCC
To examine the relationship between tumor PD-L1 
and the immune microenvironment, VSCCs were divided 
according to their level of immune checkpoint expression. 
Then, we correlated PD-L1 with the presence of immune 
cells. We found its expression to be significantly related 
with CD3+, CD20+ and CD68+ intra-tumor immunocytes 
(Figure 1B). Numbers of CD3+ T cells, CD20+ B cells 
and CD68+ monocytes/macrophages were always higher 
in PD-L1-positive VSCCs. Additionally, the amount 
of stromal CD68+ monocytes/macrophages correlated 
proportionally with the intensity of tumor PD-L1 labeling. 
With regard to immunosuppressive cell populations, 
however, no correlation was observed between PD-L1 
expression of the tumor and the amount of infiltrating Treg 
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Table 1: Clinicopathological patient characteristics
Variable Value [mean ± SD (range)]
Age (yrs) 64 ± 15 (26 - 93)
Variable Value [median (95% CI)]
Follow-up time (ms) 46.7 (31.1 - 55.8)
Variable Value [n (%)]
Tumor stage pT1a 16 (16)
pT1b 67 (65)
pT2 15 (14)
pT3 1 (1)
ND 4 (4)
Depth of stromal invasion ≤ 1mm 12 (12)
> 1mm 75 (73)
ND 16 (15)
Lymph node involvement Present 31 (30)
Absent 40 (39)
ND 32 (31)
Metastasis Present 5 (5)
Absent 94 (91)
ND 4 (4)
Tumor grade 1 12 (12)
2 66 (64)
3 24 (23)
ND 1 (1)
Lymphovascular space invasion Present 8 (8)
Absent 80 (78)
ND 15 (14)
Haemangioinvasion Present 6 (6)
Absent 82 (80)
ND 15 (14)
Local surgical treatment Wide local excision 15 (15)
Partial vulvectomy 35 (34)
Vulvectomy 49 (47)*
Punch biopsy only 4 (4)**
Tumor-free margins Present 86 (84)
Absent 17 (16)
Lymph node dissection Sentinel 4 (4)
Inguinal (uni-, bilateral) 66 (64)***
No lymph node dissection 33 (32)
(Continued)
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Variable Value [mean ± SD (range)]
Radiation therapy Vulvar 12 (12)
Inguinal 8 (8)
Vulvar & inguinal 22 (21)****
No radiation 61 (59)
Chemotherapy Chemotherapy 1 (1)
Concurrent chemoradiation 3 (3)
No chemotherapy 99 (96)
Disease status No evidence of disease 64 (62)
Recurrent disease 36 (35)
Lost to follow-up 3 (3)
Outcome Alive 61 (59)
Tumor-related death 33 (32)
Non tumor-related death 8 (8)
Lost to follow-up 1 (1)
CI, confidence interval; ms, months; ND, not determined; SD, standard deviation; yrs, years.
*, includes 9 cases of concurent pelvic exenteration.
**, surgery was not performed due to death before surgery (2) or inoperable morbidity (2).
***, in 4 cases concurrent pelvic/paraaortic lymphadenectomy was performed.
****, in 12 cases concurrent pelvic/iliac radiation therapy was performed.
Table 2: Summary of staining and HPV analysis stratified by tissue compartment
Variable Value [mean ± SD (range)]
CD3+ T cells (n) Epithelium 23.31 ± 36.36 (0 - 143)
Stroma 240.07 ± 357.42 (0.7 - 1478)
CD20+ B cells (n) Epithelium 0.32 ± 2.46 (0 - 24)
Stroma 46.58 ± 92.37 (0 - 503)
CD68+ monocytes/macrophages (n) Epithelium 4.67 ± 8.32 (0 - 38)
Stroma 22.97 ± 45 (0 - 378)
Variable Value [n (%)]
PD-L1 immunoreactivity Positive 10 (10)
Negative 93 (90)
Ki-67 immunoreactivity High 29 (28)
Low 56 (54)
ND 18 (18)
p53 immunoreactivity Positive 21 (20)
Negative 69 (67)
ND 13 (13)
p16INK4a immunoreactivity Positive 30 (29)
Negative 64 (62)
ND 9 (9)
HPV high risk Present 31 (30)
Absent 69 (67)
ND 3 (3)
ND, not determined; SD, standard deviation.
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cells and TAMs, respectively (Supplementary Figure 1). 
This was true for immunocytes found in tumor islets and 
stroma.
PD-L1 expression is associated with HPV-
negativity
In order to better understand PD-L1-related tumor 
biology, clinicopathological parameters were correlated 
with the presence of PD-L1 expression. However, no 
significant associations were observed between PD-L1 
presence and typical clinicopathological factors (Table 3). 
Based on the two pathogenic pathways known for VSCC, 
we then asked whether PD-L1 expression enriches in one 
entity. We determined (i) p53 immunoreactivity and the 
proliferation marker Ki-67 to identify VSCCs arising in 
the setting of lichen sclerosus et atrophicus [23]; (ii) high 
risk HPV and p16INK4a (a marker of HPV-transforming 
activity) to identify VSCCs driven by viral infection [24]. 
We found PD-L1 expression to occur more often in high 
risk HPV-negative VSCCs (Table 4). This finding was 
confirmed by the observation that PD-L1 positivity also 
correlated with the absence of p16INK4a. With the exception 
of PD-L1, no difference was found for immune cells 
between viral and non-viral etiology (Figure 2).
PD-L1 expression predicts impaired survival in 
VSCC
Given our observation that PD-L1 correlates 
with non-HPV pathogenesis, we analyzed whether the 
presence of PD-L1 would be of use to prognosticate 
poor outcome in VSCC. Since our cohort had an average 
age of 64 years, in which deaths from non-cancer 
illnesses are expected to occur in a higher proportion, 
the effect of mortality from causes other than VSCC was 
Figure 1: Identification of an immune microenvironment in VSCC. (A) Representative images depict various expression levels 
of membranous PD-L1 expression in VSCC (brown cell membrane, arrow) visualized by immunohistochemistry; hematoxylin (blue) was 
used for nuclear staining (bright field image, 300× magnification). (B) Expression of PD-L1 was determined by immunohistochemistry in 
103 patients with VSCC; immune cell populations were enumerated in the tumor (epithelial) and the peri-tumoral micromilieu (stroma) 
using immunohistochemistry; samples were divided into absent and present PD-L1 expression groups; frequencies of immune cells were 
calculated and plotted as number of cells per stromal and epithelial fraction, respectively, of the TMA; violin plots show the distribution of 
data points; the median, 25th and 75th percentiles and whiskers are depicted.
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Table 3: PD-L1 expression does not correlate with clincopathological parameters
Variable (number of patients evaluated)
PD-L1 expression
p-value
Positive Negative
Tumor stage (99) High 2 14 0.66
Low 8 75
NA 0 4
Depth of stromal invasion (87) > 1mm 4 32 0.16
≤ 1mm 1 50
NA 5 11
Lymph node involvement (71) Present 4 27 0.69
Absent 3 37
NA 3 29
Metastasis (99) Present 1 4 0.42
Absent 9 85
NA 0 4
Tumor grade (102) High 9 81 1.00
Low 1 11
NA 0 1
Lymphovascular space invasion (88) Present 0 8 0.59
Absent 10 70
NA 0 15
Haemangioinvasion (88) Present 0 6 1.00
Absent 10 72
NA 0 15
NA, not available.
Table 4: PD-L1 expression correlates with the absence of HPV
Variable (number of patients evaluated)
PD-L1 expression
p-value
Positive Negative
Ki-67 immunoreactivity (85) High 3 26 1.00
Low 6 50
NA 1 17
p53 immunoreactivity (90) Positive 4 17 0.23
Negative 6 63
NA 0 13
p16INK4a immunoreactivity (94) Positive 0 30 0.028
Negative 10 54
NA 0 9
HPV high risk (100) Present 0 31 0.029
Absent 10 59
NA 0 3
NA, not available.
Oncotarget92896www.impactjournals.com/oncotarget
modeled as competing risk. PD-L1 expression was able 
to discriminate between recurrence-free survival (RFS) 
rates relating a positive staining to a significantly more 
unfavorable outcome (Figure 3A). Additionally, PD-
L1 expression tended to be associated with a shorter 
cancer-specific survival (CSS, Figure 3B). We used 
Cox regression analysis and found the presence of PD-
L1 also to be an independent prognostic factor for RFS 
(Table 5). Lymph node involvement is known to be the 
most important predictor of disease outcome and was 
used as the gold standard in our analysis [25–27]. Of 
note, PD-L1 expression enhanced the risk of relapse by 
3.029 times, a hazard ratio (HR) comparable to that of 
lymphatic metastasis.
Figure 2: PD-L1 expression differs between HPV-positive and -negative cases. Tumors were grouped according to HPV-
status; stacked bar graphs illustrate relative proportions of immune parameters as determined by immunohistochemistry (immunocytes in 
the presence of PD-L1, infiltration of CD3+ or CD68+ cells only, concurrent immune infiltration of multiple immune cell types).
Figure 3: PD-L1 expression is a prognostic factor in VSCC. The membranous expression of PD-L1 in cancer cells was determined 
by immunohistochemistry; cumulative incidence analysis was performed using competing risk regression (death from VSCC was the main 
event and death from other causes the competing risk approach); results of Gray’s test are provided.
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DISCUSSION
While immune checkpoint blockade may offer a 
promising novel therapeutic approach with regard to 
locally advanced, metastatic or recurrent disease, little 
is published about the immune landscape in VSCC and 
no data are available on the clinical relevance of PD-
L1. We found PD-L1 to be expressed in VSCC within 
an immune-rich environment. The correlation of PD-L1 
with HPV-negativity and poor outcome points towards 
immune escape mechanisms in a distinct subset of 
VSCC.
We observed CD3+ T cells, CD20+ B cells and CD68+ 
monocytes/macrophages as well as Foxp3+ Treg cells and 
CD163+ TAMs to be present in peri- and intra-tumor areas. 
Data on the role that the immune system plays in VSCC 
are still scarce and conflicting. In accordance with our 
results, earlier studies have discovered evidence of CD4+ 
and CD8+ T cells in cancer nests and the peri-tumoral 
stroma [17–19]. However, their association with the 
clinical behavior of VSCC has remained largely unclear. A 
higher number of cytotoxic CD8+ T cells did not correlate 
with better outcome suggesting counteracting inhibitory 
mechanisms. In accordance with this hypothesis, higher 
levels of indoleamine 2,3-dioxygenase (IDO) expression 
were shown to be associated with poor outcome [28]. 
These findings, however, could not be replicated in a 
second study [18].
Our findings point towards a vital role of PD-
L1 in the immune escape of VSCC. The observed 
correlation between tumor-associated immune cells 
and PD-L1 expression suggests that the VSCC-directed 
immune response provokes tolerance. The more stringent 
association with immunocytes in cancer cell islets is in 
accordance with previous data showing that intra-tumor 
leukocytes reflect immune reactions against cancer with 
higher accuracy [22]. Of note, a high density of CD8+ 
T cells at the tumor site itself was shown to be crucial 
for treatment response to PD-L1 blockade [29, 30]. The 
extensive occurrence of intra-tumor T cells in VSCC 
might thus recommend immune checkpoint blockade 
as a powerful therapeutic tool. In contrast to previous 
data, we failed to identify a significant relationship 
between immunosuppressive cell populations and PD-L1 
expression in VSCC. PD-L1 has been shown to maintain 
the survival and to increase the suppressive activity of 
inducible Treg cells [31]. Similarly, PD-L1 expression 
was observed to positively correlate with the amount of 
CD163+ TAMs in melanoma [32]. Potential reasons for 
divergent findings include inadequate VSCC sample 
size given the low expression of PD-L1, tumor site 
heterogeneity not represented by TMAs and the use of 
distinct antibodies.
Overall, we found PD-L1 to be present in VSCC, 
albeit at a low frequency. A previous study evaluated 
PD-L1 in a small number of 23 VSCCs [33]. However, 
the positivity rate was slightly higher (47.83%) when 
applying our threshold to their raw data. One reason 
for this conflicting result might be the use of a different 
antibody (9A11), which recognizes an epitope in the 
cytoplasmic domain of PD-L1, while our antibody 
targets an extracellular region [34, 35]. Authors also 
showed copy number gain of PD-1 ligands-encoding 
genes to occur commonly in VSCC. Unfortunately, their 
study lacked the evaluation of PD-L1-dependent clinical 
consequences.
Table 5: Risk factors affecting recurrence-free and overall survival
Variable
Recurrence-free survival
Univariate analysis Multivariate analysis*
HR 95% CI p-value HR 95% CI p-value
PD-L1 immunoreactivity 
(positive vs. negative) 3.125 1.448 - 6.745 0.0037 3.029 1.228 - 7.471 0.0018
Lymph node involvement 
(present vs. absent) 3.076 1.546 - 6.119 0.0014 3.012 1.508 - 6.018 0.016
Variable
Overall survival
Univariate analysis Multivariate analysis*
HR 95% CI p-value HR 95% CI p-value
PD-L1 immunoreactivity 
(positive vs. negative) 2.222 0.928 - 5.32 0.07
Lymph node involvement 
(present vs. absent) 5.038 2.28 - 11.13 0.00006
CI, confidence interval; HR, Hazard ratio.
*Only variables significantly associated in the univariate analysis were included in the multivariate analysis.
Oncotarget92898www.impactjournals.com/oncotarget
We observed an unfavorable outcome in women 
with PD-L1-expressing tumors, suggesting impaired T 
cell-mediated immune responses and a microenvironment 
more permissive to tumor recurrence. Further support 
for this hypothesis comes from the observation that PD-
L1 expression did not correlate with any commonly 
recognized feature of greater malignant potential. Our data 
suggest that PD-L1-based immune evasion mechanisms 
occur primarily in HPV-negative VSCCs. In penile 
cancer, PD-L1 expression was also found to be mainly 
expressed in HPV-negative tumors [36]. In Epstein-
Barr-positive lymphoproliferative disorders and cervical 
cancer, however, viral infection represents a mechanism 
to provoke PD-L1 expression [37, 38]. In head and neck 
tumors conflicting results were published with regard to 
the HPV-dependence of PD-L1 [39, 40]. Thus, additional 
functional studies are needed to clarify the role HPV plays 
in PD-L1 induction.
Immune checkpoint blockade has been a game-
changer in the field of tumor treatment and the 
identification of a biomarker that predicts the response 
to PD-L1 inhibition is essential. While PD-L1-negative 
tumors might also benefit from checkpoint inhibitors and 
some PD-L1-positive tumors do not respond to treatment, 
an increased probability of therapeutic response has been 
observed in tumors defined by the presence of PD-L1 [41, 
42]. Accordingly, our observation of PD-L1 expression 
in the tumor bed of VSCC could be valuable in guiding 
clinical decision making. Additionally, our data suggest 
that the HPV status could potentially stratify patients for 
trials with anti-PD-L1 treatment.
To the best of our knowledge, this is the first study 
analyzing the clinical impact of PD-L1 expression in 
VSCC. The strength of our analysis lies in the compilation 
of immunological markers and diverse clinical as well 
as pathological data. A potential limitation of our study 
is the utilization of TMA. Although reliable for the 
determination of antigen expression, a heterogeneous 
protein distribution could potentially influence results [43]. 
In cervical squamous cell cancer, a tumor comparable to 
VSCC, both diffuse and focal expression of PD-L1 was 
observed [44]. Interestingly, women with homogeneously 
PD-L1-stained cervical malignancies showed poorer 
survival than those with a heterogeneous labeling. In the 
light of these data, we cannot rule out a TMA-dependent 
selection bias that favored diffuse PD-L1 expression. 
Our multivariate analysis identified PD-L1 expression as 
an independent prognostic factor of RFS but not of OS. 
Despite having a long-term follow-up, it may have been 
too short to identify independent prognostic factors of OS. 
Survival rates could have been influenced by (i) the study 
population with a high number of early stages; and (ii) 
therapy with curative intent in recurrent cases.
In summary, our study provides evidence that 
inhibitory pathways are operational in VSCC, arresting the 
tumor-specific immune response and influencing outcome. 
Our findings will hopefully boost the development of 
immunotherapy in VSCC. While further efforts must be 
made to validate our findings of PD-L1 as a prognostic 
factor and determine its value as a predictive biomarker, 
checkpoint blockade could be the leading path to increased 
treatment success in VSCC.
MATERIALS AND METHODS
Patients and specimens
The retrospective study population included 103 
patients with primary VSCC diagnosed at the University 
of Bonn between 2002 and 2013. Women who underwent 
neoadjuvant treatment were excluded. Patients were 
treated according to the S2k guideline of the German 
Cancer Society and the German Society for Gynecology 
and Obstetrics. Our cohort had a high number of 
women not treated with lymph node dissection. Due to 
cardiovascular comorbidities, 20 patients with early-stage 
tumors (pTIb/II) did not undergo lymphonodectomy; 
clinically and sonographically lymph nodes appeared to be 
unaffected. Additionally, the presence of lymphovascular 
space invasion was recorded, known to be a risk factor for 
lymph node metastasis [45]. In our cohort, however, no 
significant association between lymph node involvement 
and lymphovascular space invasion was noted, likely 
due to the fact that the detection is challenging in the 
absence of lymphatic endothelium-specific markers [46]. 
Baseline characteristics were obtained from a clinical 
database. Follow-up data were updated until August 2016. 
Histopathological diagnosis was made based on World 
Health Organization (WHO) criteria. The 2010 revision of 
the International Federation of Gynecology and Obstetrics 
(FIGO) system was used to assign the tumor grade; the 
7th TNM classification of the Union for International 
Cancer Control (UICC) was used to determine the tumor 
stage. For tumors diagnosed before 2009, stages were re-
classified according to the updated version. The study was 
approved by the Institutional Review Board of the Medical 
Faculty of the University of Bonn, Germany (228/15).
Tissue microarray (TMA) construction
The TMA was created from archival formalin-fixed 
paraffin-embedded tissue (FFPE) specimens. Sections 
stained with hematoxylin and eosin (HE) were used to 
identify representative tumor areas. For each case, one 1 
mm core biopsy (0.785mm2) was taken from the selected 
cancer nests and arranged in TMA blocks.
Immunohistochemistry
Immunostaining of PD-L1, CD3, CD20 and 
CD68 was performed on TMAs using an automated 
staining system (BenchMark ULTRA; Ventana Medical 
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Systems, Tucson, Arizona, USA) and the Ventana 
amplifier detection kit for visualization. Additionally, in 
a subset of our cohort (42 samples) staining of CD163 
and Foxp3 was performed on serial 4μm sections using 
an automated staining system (DAKO TechMate 500; 
DAKO, Glostrup, Denmark) and the streptavidin-biotin-
peroxidase/DAB technique (DAKO) for visualization. To 
determine PD-L1 expression we employed an antibody 
that is FDA-approved for selecting non-small cell lung 
cancer patients for treatment with the anti-PD-1 antibody 
pembrolizumab [35]. Primary antibodies included the 
following: mouse anti-human PD-L1 IgG1 monoclonal 
antibody (clone 22C3, dilution1:25; Dako, Glostrup, 
Denmark), mouse anti-human Ki-67 IgG1 monoclonal 
antibody (clone MIB-1, dilution 1:500; Dako), mouse 
anti-human p53 IgG2b monoclonal antibody (clone DQ-
7, dilution 1:500; Dako), CINtec© Histology kit for the 
evaluation of p16INK4a (Roche, Basel, Switzerland), mouse 
anti-human CD3 IgG2a monoclonal antibody (clone PS1, 
dilution 1:50; Novocastra, Newcastle Upon Tyne, United 
Kingdom), mouse anti-human CD20 IgG2a monoclonal 
antibody (clone L26, dilution 1:2000; Dako), mouse anti-
human CD68 IgG3 monoclonal antibody (clone PG-M1, 
dilution 1:250, Dako), mouse anti-human CD163 IgG1 
monoclonal antibody (clone 10D6, dilution 1: 1250, Leica 
Biosystems, Wetzlar, Germany), mouse anti-human Foxp3 
IgG1 monoclonal antibody (clone 236A/E7, dilution 1: 50, 
Abcam, Cambridge, UK).
Evaluation of immunoreactions
Immunostained cells were analyzed with a Leica 
DM LB2 microscope (Leica Microsystems, Wetzlar, 
Germany) with the Pannoramic Viewer (3DHISTECH Ltd., 
Budapest, Hungary) or the Axio Observer D1 microscope 
(Zeiss, Jena, Germany) with the AxioVision 4.7 software 
(Zeiss). As a negative control for PD-L1 staining, we used 
sections of kidney, as a positive control sections of tonsil 
(Supplementary Figure 2). The membranous expression 
of PD-L1 on tumor cells was scored positive only if the 
immunoreactivity showed a honeycomb pattern (i.e. 
continuously stained cell membranes); cytoplasmic 
staining of PD-L1 was disregarded. Our analysis is based 
on an integrated proportion score that aims to harmonize 
different PD-L1 immunoassays [47]. In detail, a four-
tier scoring system was applied to categorize the staining 
intensity (0, no staining; 1, low staining; 2, moderate 
staining; 3, high staining). Additionally, the percentage 
of PD-L1-stained tumor cells was estimated (0, <1%; 1, 
≥1%; 2 ≥5%; 3, ≥10%; 4, ≥25%; 5, ≥50%). Malignancies 
with a staining intensity ≥ 2 in ≥ 5% of tumor cells were 
regarded as PD-L1 positive [48]. For Ki-67, a nuclear 
staining of cancer cells was interpreted as positive and the 
percentage of labeled cells in the vulvar epithelium was 
recorded; for p53, a nuclear staining in >25% of tumor cells 
was graded positive [49, 50]; for p16INK4a, a continuous 
strong nuclear plus cytoplasmic labeling of the basal cells 
with extension upward involving ≥30% of the epithelial 
thickness was regarded as positive [49, 51, 52]. Immune cell 
populations were determined separately in the epithelium 
and the stroma. T cells were identified by membranous and 
cytoplasmic expression of CD3, B cells by membranous and 
cytoplasmic expression of CD20, monocytes/macrophages 
by cytoplasmic expression of CD68, TAMs by membranous 
and cytoplasmic expression of CD163, Treg cells by nuclear 
staining of Foxp3. CD3+ T cells, CD20+ B cells and CD68+ 
monocytes/macrophages were enumerated using the whole 
core area of the TMA (values are given as the number of 
immune cells per stromal and epithelial fraction of the 
TMA, respectively). Treg cells and TAMs were determined 
in three high-power fields (HPFs) with maximum 
infiltration and set in relation to the relative amount of 
tumor and stroma of these HPFs (values are given as the 
mean percentage of immune cells per stromal and epithelial 
fraction of individual HPFs). Treg cells were enumerated; 
TAMs were recorded digitally using a semi-automated 
computerized method as described before [21].
DNA extraction
After deparaffinization, tumor tissue was 
macrodissected from unstained slides and tissue was lysed 
with proteinase K overnight. Subsequently, extraction of 
DNA from FFPE-embedded tissue DNA was carried out 
with the BioRobot M48 Robotic Workstation and the 
corresponding MagAttract DNA Mini M48 Kit (Qiagen, 
Hilden, Germany) following the manufacturer’s protocol. 
Quality of genomic DNA was assessed by agarose gel 
electrophoresis. DNA concentration of each sample was 
determined using Nanodrop 2000 (PeqLab, Erlangen, 
Germany).
HPV analysis
The HPV Type 3.5 LCD-Array Kit was used for 
the determination of HPV subtypes by hybridization to 
HPV-specific DNA probes (Chipron, Berlin, Germany). 
Amplification of HPV-specific DNA segments (L1 
region) was achieved using the primer sets HPV ‘125’ and 
HPV MY09/MY11. Ten microliters of the amplification 
products were hybridized to HPV type-specific capture 
probes fixed to an LCD array chip. All steps were 
performed according to manufacturer’s recommendations.
Statistical analysis
Statistical analysis was carried out using ‘R’ 
version 3.2.3 (The R Foundation for Statistical 
Computing, Vienna, Austria). Comparisons between 
PD-L1 expression and continuous data were performed 
using the Kruskal-Wallis test; comparisons between 
PD-L1 expression (positive, negative) and categorical 
variables using the Fisher's exact test. Ki-67 staining in 
Oncotarget92900www.impactjournals.com/oncotarget
≥ 30% of the epithelium was used as a cut-off point to 
assign tumors into high and low reactivity groups [23]. 
Poor-differentiation - grades 2,3 [53] - and advanced 
tumor stages - stages pT2, 3 [54] - have been shown 
to result in a poorer prognosis and, thus, thresholds 
were set between grades 2,3 and 1 and between stages 
pT2, 3 and pT1, respectively. Cumulative incidence 
analysis (RFS, CSS) was modeled using the competing 
risk approach and curves were compared with Gray’s 
test [55]. Multivariate survival analysis (RFS, OS) was 
done using the Cox's proportional hazard regression 
model. The confidence interval for the median follow-
up time was calculated using quantiles of the binomial 
distribution.
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